RMD · XBRL financial data

ResMed financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (RMD's year ends in late June)

In millions of dollars	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026	Q1 FY27Sep 30, 2026
Revenue from contracts with customers	1,163	1,197	1,223*	1,225	1,282	1,292	1,348*	1,336	1,423	1,431	1,464*	1,415
Cost of goods and services sold	516	504	508*	507	531	525	528*	515	544	540	602*	544
Gross profit	647	693	716*	717	751	766	820*	821	879	891	861*	871
Research and development	74	77	81*	80	81	84	86*	87	91	94	106*	103
Selling, general and administrative	222	230	242*	239	242	245	265*	259	278	286	296*	315
Total operating expenses	372	318	334*	330	334	340	366*	374	387	391	413*	418
Operating income (loss)	275	375	381*	387	417	426	455*	447	492	500	449*	453
Interest expense	—	—	—	—	—	—	—	7	—	—	—	5
Other income (expense)	(1)	(2)	(3)*	(2)	2	(4)	(1)*	(4)	(5)	(1)	1*	0
Income tax expense (benefit)	51	75	65*	72	74	53	78*	98	104	104	91*	121
Net income (loss)	209	300	292*	311	345	365	380*	349	393	399	383*	418
Earnings per share, basic USD per share	1.42	2.04	1.99*	2.12	2.35	2.49	2.59*	2.38	2.69	2.74	2.65*	2.93
Earnings per share, diluted USD per share	1.42	2.04	1.98*	2.11	2.34	2.48	2.58*	2.37	2.68	2.74	2.64*	2.92
Weighted average shares, basic millions of shares	147	147	147*	147	147	147	146*	146	146	145	145*	143
Weighted average shares, diluted millions of shares	148	147	148*	148	147	147	147*	147	146	146	145*	143

Fiscal quarters (RMD's year ends in late June)

In millions of dollars	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026	Q1 FY27Sep 30, 2026
Cash and cash equivalents	210	238	238	426	522	933	1,209	1,384	1,417	1,661	1,469	1,011
Accounts receivable	730	779	837	811	860	908	939	907	986	999	1,036	972
Inventory	933	829	822	918	882	863	928	946	922	912	946	1,021
Prepaid and other current assets	505	505	460	486	572	505	429	389	494	493	416	504
Total current assets	2,378	2,351	2,358	2,641	2,836	3,208	3,506	3,626	3,819	4,064	4,325	3,509
Property and equipment, net	552	540	548	560	520	535	551	564	564	567	582	602
Right-of-use asset	153	147	151	157	151	153	167	162	166	162	153	197
Goodwill	2,862	2,836	2,842	2,886	2,805	2,849	3,047	3,044	3,044	3,043	2,910	2,908
Total assets	6,905	6,815	6,872	7,222	7,141	7,567	8,174	8,308	8,503	8,784	8,966	8,212
Accounts payable	202	177	238	249	220	223	278	267	250	273	309	321
Accrued liabilities	332	356	378	366	353	386	402	396	392	446	495	480
Total current liabilities	764	773	911	904	852	941	1,019	1,256	1,248	1,351	1,395	1,324
Lease liability, non-current	141	136	141	144	139	138	153	148	154	150	137	169
Total liabilities	2,423	2,185	2,008	2,027	1,888	2,021	2,207	2,187	2,182	2,292	2,381	2,264
Retained earnings	4,540	4,770	4,992	5,225	5,492	5,779	6,081	6,342	6,647	6,959	7,255	7,579
Total stockholders' equity	4,482	4,630	4,864	5,195	5,253	5,546	5,968	6,121	6,321	6,492	6,585	5,948
Total liabilities and equity	6,905	6,815	6,872	7,222	7,141	7,567	8,174	8,308	8,503	8,784	8,966	8,212
Common shares outstanding (cover page) millions of shares	147	147	147	147	147	147	146	146	146	145	144	141

Fiscal quarters (RMD's year ends in late June)

In millions of dollars	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026	Q1 FY27Sep 30, 2026
Net income (loss)	209	300	292*	311	345	365	380*	349	393	399	383*	418
Stock-based compensation	20*	20*	21*	20	23*	24*	25*	21	29*	27*	27*	29
Depreciation and amortization	45	43	44*	45	46	44	64*	48	50	59	45*	42
Net cash from operating activities	273*	402*	440*	326	309*	579*	539*	457	340*	554*	455*	422
Purchases of property and equipment	23*	21*	25*	18	21*	21*	31*	43	29*	34*	51*	49
Net cash from investing activities	(41)*	(33)*	(47)*	2	(37)*	(32)*	(134)*	(53)	(51)*	(58)*	(384)*	392
Proceeds from issuing common stock	20*	5*	28*	8	27*	9*	30*	8	30*	7*	29*	4
Share repurchases	50*	50*	50*	50	75*	75*	100*	150	175*	175*	200*	936
Dividends paid	71*	70*	71*	78	78*	78*	78*	88	88*	87*	87*	95
Proceeds from long-term debt	0*	0*	0*	0	0*	0*	0*	—	—	—	year only	—
Repayments of long-term debt	130*	220*	300*	30	5*	0*	5*	0	5*	0*	5*	250
Net cash from financing activities	(239)*	(336)*	(393)*	(151)	(148)*	(144)*	(164)*	(230)	(258)*	(255)*	(263)*	(1,278)
Net change in cash	1*	28*	0*	188	96*	411*	277*	174	33*	243*	(191)*	(458)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Resmed	1,011	1,415	422	140.7M	—	Q1 FY27 10-QSep 30, 2026
Dexcom	961	1,345	326*	373.0M	—	Q3 FY26 10-QSep 30, 2026
GE HealthCare Technologies	2,826	5,513	907*	452.1M	—	Q3 FY26 10-QSep 30, 2026
Edwards Lifesciences	2,907	1,741	652*	576.4M	—	Q2 FY26 10-QJun 30, 2026
STERIS	482	1,493	367	97.5M	—	Q1 FY27 10-QJun 30, 2026
Insulet	535	802	88*	69.4M	—	Q2 FY26 10-QJun 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
Becton Dickinson	708	4,983	not reported	272.4M	—	Q3 FY26 10-QJun 30, 2026
Zimmer Biomet Holdings	410	2,177	448*	190.7M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.